Florida Attorney General Launches Anticompetitive Investigation into CVS Caremark Over Pharmacy Practices
核心洞察
Florida Attorney General James Uthmeier has launched an investigation into CVS Health and its PBM Caremark (搜索) over concerns of anticompetitive conduct that may disadvantage independent pharmacies.
The probe will examine whether CVS steers patients toward its own pharmacies, reimburses affiliated stores at higher rates, and imposes burdensome audits on smaller competitors.
CVS must produce thousands of records and sworn testimony by July 28, 2026, covering reimbursement practices, contracts, audits, rebates, and patient steering.
Florida Attorney General James Uthmeier announced Tuesday the launch of an investigation into CVS Health and its pharmacy benefit manager (PBM), Caremark (搜索), amid growing concerns that the vertically integrated healthcare giant may be using its market power to disadvantage independent pharmacies and limit consumer choice across the state.
The probe centers on whether CVS Health's ownership of both one of the nation's largest PBMs and approximately 800 retail pharmacies in Florida creates unfair competitive advantages that could affect prescription drug access and pricing. Caremark (搜索) is among the three largest PBMs in the United States, a group that collectively processes about 80% of all prescriptions nationwide.
Scope of the Investigation
The investigation will examine multiple allegations of anticompetitive conduct, including whether Caremark (搜索) steers patients toward CVS-owned pharmacies, reimburses affiliated stores at higher rates than independent pharmacies for the same prescriptions, imposes audits that result in payment clawbacks, and uses restrictive contracts that place financial pressure on smaller competitors.
As part of the probe, Uthmeier issued a civil investigative demand — a type of administrative subpoena — requiring CVS to produce thousands of records covering reimbursement practices, pharmacy contracts, audits, rebates, patient steering, treatment of affiliated versus independent pharmacies, and future expansion plans. CVS must comply by July 28, 2026.
State officials have not alleged specific violations of Florida law or announced any enforcement action against CVS Health at this stage. It remains unclear whether the investigation will find evidence of differential reimbursement, improper patient steering, or other anti-competitive conduct.
Industry Context and National Scrutiny
PBMs serve as intermediaries between insurers, drug manufacturers, and pharmacies, negotiating rebates with drugmakers, determining medication coverage, establishing reimbursement rates, and managing prescription drug networks. In recent years, these entities have faced growing scrutiny from lawmakers, independent pharmacists, and consumer advocates who argue that industry consolidation has given a small number of companies significant influence over prescription drug access and pricing.
Critics contend that vertically integrated companies — those that own both PBMs and pharmacies — may have incentives to favor their own retail operations. Independent pharmacies across the country have warned that reimbursement rates and administrative requirements imposed by PBMs contribute to store closures, particularly in rural and underserved communities.
Other states have moved to add restrictions on PBMs. Arkansas passed a law last year banning PBMs from owning or operating pharmacies, though it was enjoined following lawsuits from Express Scripts, Caremark (搜索), and Optum Rx. Tennessee also passed similar legislation, which is currently facing legal challenges from drug middlemen and the PBM lobby.
Statements from Key Stakeholders
Attorney General James Uthmeier framed the investigation as an effort to protect consumers and independent pharmacies. "Florida families and seniors deserve access to affordable medication and real pharmacy choices — not a system rigged by one giant corporation that may favor its own stores and squeeze out competitors," Uthmeier said. "This investigation will uncover the truth and protect fair competition for all Floridians."
Agency for Health Care Administration Secretary Shevaun Harris added, "Floridians expect a health care system that works for them, not against them. The Attorney General's action is an important step toward that future, and AHCA is proud to stand alongside this effort to ensure accountability of PBMs."
Florida Pharmacy Association incoming President Aneesh Lakhani praised the investigation, stating, "The Attorney General's action today sends a clear and necessary message: the era of unchecked PBM abuse in Florida is over. My patients deserve better. Florida deserves better. The system wasn't broken, PBMs broke the system. We will not rest until they are held fully accountable."
CVS Health's Response
CVS Health said it plans to cooperate with the state while disputing claims that PBMs are responsible for high prescription drug costs. "Drugmakers alone set the price of prescription drugs, and blaming a PBM for high drug prices is like blaming an umbrella for the rain," a CVS spokesperson said in a statement.
The outcome of the Florida investigation could have significant implications for hundreds of pharmacies, prescription drug access, and competition within the state's health care marketplace, while also contributing to the broader national debate over the role of PBMs in the U.S. healthcare system.